Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K4MU
|
|||
| Former ID |
DIB006039
|
|||
| Drug Name |
Crobenetine
|
|||
| Synonyms |
CROBENETINE; CROBENETINE); BIII-890-CL; Crobenetine; Crobenetine hydrochloride; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H33NO2
|
|||
| Canonical SMILES |
CC(CN1CCC2(C3=C(CC1C2(C)C)C(=CC=C3)O)C)OCC4=CC=CC=C4
|
|||
| InChI |
1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1
|
|||
| InChIKey |
VCCBCXVFGHTDQN-UODBTFMRSA-N
|
|||
| CAS Number |
221019-25-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02251197) Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke. U.S. National Institutes of Health. | |||
| REF 2 | Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.